Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

NCT04536077 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Celldex decision

Conditions

Pancreatic Cancer
Cancer of the Pancreas
Pancreas Cancer

Interventions

DRUG: CDX-301
DRUG: CDX-1140
PROCEDURE: Research blood draw

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]